Compare CLB & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLB | CTMX |
|---|---|---|
| Founded | 1936 | 2008 |
| Country | United States | United States |
| Employees | 3300 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 864.2M | 716.9M |
| IPO Year | 2023 | 2015 |
| Metric | CLB | CTMX |
|---|---|---|
| Price | $12.47 | $3.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $12.50 | $12.10 |
| AVG Volume (30 Days) | 420.1K | ★ 2.9M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $526,520,000.00 | $76,201,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.75 | $7.61 |
| P/E Ratio | $114.00 | ★ $22.58 |
| Revenue Growth | ★ 0.51 | N/A |
| 52 Week Low | $9.79 | $1.90 |
| 52 Week High | $20.36 | $8.21 |
| Indicator | CLB | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 61.67 | 57.65 |
| Support Level | $11.75 | $3.43 |
| Resistance Level | $12.86 | $3.96 |
| Average True Range (ATR) | 0.45 | 0.20 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 84.90 | 67.83 |
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.